Efficacy and safety of aumolertinib in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis: a single‑center retrospective study - Takeaways - MDSpire

Efficacy and safety of aumolertinib in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis: a single‑center retrospective study

  • By

  • Lulu Zhuang

  • Xiaoyan Yin

  • Xiaoli Liu

  • Defeng Liu

  • Zhonghui Wei

  • Yu Chen

  • Kaikai Zhao

  • Yankang Li

  • Jinming Yu

  • Xiangjiao Meng

  • February 4, 2025

  • 0 min

Share

  • 1

    Leptomeningeal metastasis (LM) in EGFR-mutated non-small cell lung cancer (NSCLC) significantly worsens prognosis and quality of life.

  • 2

    Aumolertinib, a third-generation EGFR-TKI, shows promise in treating EGFR-mutated NSCLC with LM due to its enhanced blood-brain barrier penetration.

  • 3

    In a retrospective study, 79 patients treated with aumolertinib demonstrated improved median progression-free survival compared to first-generation EGFR-TKIs.

  • 4

    The study found aumolertinib treatment resulted in a median overall survival of 26.6 months, indicating its potential effectiveness in this patient population.

  • 5

    Real-world evidence on aumolertinib's efficacy in EGFR-mutated NSCLC with LM is limited, highlighting the need for further research.

Original Source(s)

Efficacy and safety of aumolertinib in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis: a single‑center retrospective study

  • by Lulu Zhuang, Xiaoyan Yin, Xiaoli Liu, Defeng Liu, Zhonghui Wei, Yu Chen, Kaikai Zhao, Yankang Li, Jinming Yu, Xiangjiao Meng

  • February 4, 2025

Related Content

An LDH-based prognostic model for extensive-stage small-cell lung cancer patients treated with chemo-immunotherapy and consolidative thoracic radiotherapy

Risk prediction models for venous thromboembolism in lung cancer patients after surgery: a systematic review and meta-analysis

Case report: Helical tomotherapy-based whole lung irradiation with simultaneous integrated boost for pulmonary metastatic Ewing’s sarcoma: a case series report and feasibility analysis